These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 12756111

  • 21. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.
    Berger W, De Chandt MT, Cairns CB.
    Int J Clin Pract; 2007 Apr; 61(4):663-76. PubMed ID: 17394438
    [Abstract] [Full Text] [Related]

  • 22. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.
    Wenzel SE, Kamada AK.
    Ann Pharmacother; 1996 Apr; 30(7-8):858-64. PubMed ID: 8826571
    [Abstract] [Full Text] [Related]

  • 23. Lack of Long-Term Neurologic Efficacy of Zileuton in Sjögren-Larsson's Syndrome.
    Sarret C, Pichard S, Afenjar A, Boespflug-Tanguy O.
    Neuropediatrics; 2017 Jun; 48(3):205-206. PubMed ID: 28388737
    [No Abstract] [Full Text] [Related]

  • 24. Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis.
    Collawn C, Rubin P, Perez N, Bobadilla J, Cabrera G, Reyes E, Borovoy J, Kershenobich D.
    Am J Gastroenterol; 1992 Mar; 87(3):342-6. PubMed ID: 1539569
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers.
    Awni WM, Locke C, Dube LM, Cavanaugh JH.
    J Clin Pharmacol; 1997 May; 37(5):388-94. PubMed ID: 9156371
    [Abstract] [Full Text] [Related]

  • 26. Treatment of disseminated granuloma annulare with a 5-lipoxygenase inhibitor and vitamin E.
    Smith KJ, Norwood C, Skelton H.
    Br J Dermatol; 2002 Apr; 146(4):667-70. PubMed ID: 11966702
    [Abstract] [Full Text] [Related]

  • 27. A-78773: a selective, potent 5-lipoxygenase inhibitor.
    Bell RL, Brooks DW, Young PR, Lanni C, Stewart AO, Bouska J, Malo PE, Carter GW.
    J Lipid Mediat; 1993 Apr; 6(1-3):259-64. PubMed ID: 8395248
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and tolerability of oral lactoferrin supplementation in mild to moderate acne vulgaris: an exploratory study.
    Mueller EA, Trapp S, Frentzel A, Kirch W, Brantl V.
    Curr Med Res Opin; 2011 Apr; 27(4):793-7. PubMed ID: 21303195
    [Abstract] [Full Text] [Related]

  • 29. 5-Lipoxygenase inhibition: a new treatment strategy for Sjögren-Larsson syndrome.
    Willemsen MA, Rotteveel JJ, Steijlen PM, Heerschap A, Mayatepek E.
    Neuropediatrics; 2000 Feb; 31(1):1-3. PubMed ID: 10774987
    [Abstract] [Full Text] [Related]

  • 30. The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.
    Awni WM, Cavanaugh JH, Braeckman RA, Chu SY, Patterson KJ, Machinist JM, Granneman GR.
    Clin Pharmacokinet; 1995 Feb; 29 Suppl 2():49-61. PubMed ID: 8620671
    [Abstract] [Full Text] [Related]

  • 31. Zileuton use and phenotypic features in asthma.
    Thalanayar Muthukrishnan P, Nouraie M, Parikh A, Holguin F.
    Pulm Pharmacol Ther; 2020 Feb; 60():101872. PubMed ID: 31841698
    [Abstract] [Full Text] [Related]

  • 32. [5-lipoxygenase inhibitors in asthma therapy].
    Tanaka R.
    Nihon Rinsho; 1996 Nov; 54(11):3040-4. PubMed ID: 8950951
    [Abstract] [Full Text] [Related]

  • 33. Safety and clinical efficacy of zileuton in patients with chronic asthma.
    Lazarus SC, Lee T, Kemp JP, Wenzel S, Dubé LM, Ochs RF, Carpentier PJ, Lancaster JF.
    Am J Manag Care; 1998 Jun; 4(6):841-8. PubMed ID: 10181070
    [Abstract] [Full Text] [Related]

  • 34. Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
    Awni WM, Granneman GR, Locke CS, Brandwein SR, Dube LM.
    Eur J Clin Pharmacol; 1995 Jun; 48(2):155-60. PubMed ID: 7589031
    [Abstract] [Full Text] [Related]

  • 35. Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome.
    Willemsen MA, Lutt MA, Steijlen PM, Cruysberg JR, van der Graaf M, Nijhuis-van der Sanden MW, Pasman JW, Mayatepek E, Rotteveel JJ.
    Eur J Pediatr; 2001 Dec; 160(12):711-7. PubMed ID: 11795678
    [Abstract] [Full Text] [Related]

  • 36. Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation.
    Myrdal PB, Karlage K, Kuehl PJ, Angersbach BS, Merrill BA, Wightman PD.
    Carcinogenesis; 2007 May; 28(5):957-61. PubMed ID: 17114645
    [Abstract] [Full Text] [Related]

  • 37. The pharmacokinetics of zileuton in healthy young and elderly volunteers.
    Braeckman RA, Granneman GR, Locke CS, Machinist JM, Cavannaugh JH, Awni WM.
    Clin Pharmacokinet; 1995 May; 29 Suppl 2():42-8. PubMed ID: 8620670
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
    Rubin P, Dubé L, Braeckman R, Swanson L, Hansen R, Albert D, Carter G.
    Agents Actions Suppl; 1991 May; 35():103-16. PubMed ID: 1781415
    [Abstract] [Full Text] [Related]

  • 40. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
    Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM.
    Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1447-51. PubMed ID: 8256883
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.